Literature DB >> 11123000

The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse.

C L Bowden1.   

Abstract

Bipolar disorder is marked by frequent recurrences, a course from childhood or early adulthood until death, marked increased rates of suicide, and substantial functional morbidity. Maintenance treatment is generally recommended to reduce the ravages of the illness. This article reviews the evidence that lithium, divalproex, and carbamazepine may reduce suicidal risk. It reviews the evidence for relapse prevention for lithium, valproate, and other drugs often employed in the maintenance phase treatment of bipolar disorder. Both lithium and divalproex appear beneficial in prevention of relapse, although recent studies indicate more modest effects for lithium than did early studies from the 1970s.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123000     DOI: 10.1007/s11920-000-0007-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  33 in total

1.  The treatment of manic psychoses by the administration of lithium salts.

Authors:  M SCHOU; N JUEL-NIELSEN; E STROMGREN; H VOLDBY
Journal:  J Neurol Neurosurg Psychiatry       Date:  1954-11       Impact factor: 10.154

2.  Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder.

Authors:  J R Calabrese; G A Delucchi
Journal:  Am J Psychiatry       Date:  1990-04       Impact factor: 18.112

3.  Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study.

Authors:  J Aagaard; P Vestergaard
Journal:  J Affect Disord       Date:  1990-04       Impact factor: 4.839

4.  A controlled evaluation of lithium prophylaxis in affective disorders.

Authors:  R L Cundall; P W Brooks; L G Murray
Journal:  Psychol Med       Date:  1972-08       Impact factor: 7.723

5.  Efficacy of lithium as acute treatment of manic-depressive illness.

Authors:  P E Stokes; C A Shamoian; P M Stoll; M J Patton
Journal:  Lancet       Date:  1971-06-26       Impact factor: 79.321

6.  Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders.

Authors:  P C Baastrup; J C Poulsen; M Schou; K Thomsen; A Amdisen
Journal:  Lancet       Date:  1970-08-15       Impact factor: 79.321

Review 7.  The risk of suicide in patients with bipolar disorders.

Authors:  S G Simpson; K R Jamison
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

8.  Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study.

Authors:  T Okuma; I Yamashita; R Takahashi; H Itoh; S Otsuki; S Watanabe; K Sarai; H Hazama; K Inanaga
Journal:  Pharmacopsychiatry       Date:  1990-05       Impact factor: 5.788

9.  Suicidality in patients with pure and depressive mania.

Authors:  S C Dilsaver; Y W Chen; A C Swann; A M Shoaib; K J Krajewski
Journal:  Am J Psychiatry       Date:  1994-09       Impact factor: 18.112

10.  Relapse and impairment in bipolar disorder.

Authors:  M J Gitlin; J Swendsen; T L Heller; C Hammen
Journal:  Am J Psychiatry       Date:  1995-11       Impact factor: 18.112

View more
  1 in total

Review 1.  Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Authors:  Gin S Malhi; Michelle Tanious; Pritha Das; Carissa M Coulston; Michael Berk
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.